Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Radiotherapy for Metastatic Epidural Spinal Cord Compression with Increased Doses: Final Results of the RAMSES-01 Trial

dc.contributor.authorRades, Dirk
dc.contributor.authorLomidze, Darejan
dc.contributor.authorJankarashvili, Natalia
dc.contributor.authorLópez Campos, Fernando
dc.contributor.authorNavarro Martín, Arturo
dc.contributor.authorSegedin, Barbara
dc.contributor.authorGroselj, Blaz
dc.contributor.authorStaackmann, Christian
dc.contributor.authorKristiansen, Charlotte
dc.contributor.authorDennis, Kristopher
dc.contributor.authorSchild, Steven E.
dc.contributor.authorCacicedo, Jon
dc.date.accessioned2024-07-01T09:09:06Z
dc.date.available2024-07-01T09:09:06Z
dc.date.issued2024-03-14
dc.date.updated2024-06-13T10:18:03Z
dc.description.abstractSimple Summary Patients with MESCC and favorable survival prognoses assigned to radiotherapy alone may benefit from increased doses. In a multi-center phase 2 trial, patients receiving 15 x 2.633 Gy or 18 x 2.333 Gy were evaluated and subsequently compared to a historical control group receiving 10 x 3.0 Gy. The phase 2 cohort, including 50 (of 62 planned) evaluable patients, showed promising results regarding 12-month local progression-free survival (LPFS), 12-month overall survival (OS), improvement of motor and sensory functions, post-radiotherapy ambulatory status, and relief of pain and distress. Radiotherapy with 15 x 2.633 Gy or 18 x 2.333 Gy was well tolerated and appeared more effective than 10 x 3.0 Gy with respect to LPFS and improvement of motor function.Abstract Patients with metastatic epidural spinal cord compression (MESCC) and favorable survival prognoses may benefit from radiation doses exceeding 10 x 3.0 Gy. In a multi-center phase 2 trial, patients receiving 15 x 2.633 Gy (41.6 Gy10) or 18 x 2.333 Gy (43.2 Gy10) were evaluated for local progression-free survival (LPFS), motor/sensory functions, ambulatory status, pain, distress, toxicity, and overall survival (OS). They were compared (propensity score-adjusted Cox regression) to a historical control group (n = 266) receiving 10 x 3.0 Gy (32.5 Gy10). In the phase 2 cohort, 50 (of 62 planned) patients were evaluated for LPFS. Twelve-month rates of LPFS and OS were 96.8% and 69.9%, respectively. Motor and sensory functions improved in 56% and 57.1% of patients, and 94.0% were ambulatory following radiotherapy. Pain and distress decreased in 84.4% and 78.0% of patients. Ten and two patients experienced grade 2 and 3 toxicities, respectively. Phase 2 patients showed significantly better LPFS than the control group (p = 0.039) and a trend for improved motor function (p = 0.057). Ambulatory and OS rates were not significantly different. Radiotherapy with 15 x 2.633 Gy or 18 x 2.333 Gy was well tolerated and appeared superior to 10 x 3.0 Gy.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2072-6694
dc.identifier.pmid38539484
dc.identifier.urihttps://hdl.handle.net/2445/214024
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cancers16061149
dc.relation.ispartofCancers, 2024, vol. 16, num. 6
dc.relation.urihttps://doi.org/10.3390/cancers16061149
dc.rightscc by (c) Rades, Dirk et al, 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationRadioteràpia
dc.subject.classificationMedul·la espinal
dc.subject.otherRadiotherapy
dc.subject.otherSpinal Cord
dc.titleRadiotherapy for Metastatic Epidural Spinal Cord Compression with Increased Doses: Final Results of the RAMSES-01 Trial
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
cancers-16-01149-v2.pdf
Mida:
1.3 MB
Format:
Adobe Portable Document Format